Drug Sponsors

Teva to acquire Labrys Biologics for $825 million

Wednesday, June 4, 2014 12:57 PM

Teva Pharmaceutical Industries will acquire Labrys Biologics, a privately held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, broadening Teva’s array of biotechnology assets and capabilities.

More... »

WIRB Copernicus Group

Provence Technologies acquires Synprosis, rebrands as Provepep

Tuesday, June 3, 2014 09:22 AM

Provence Technologies Group, a specialist fine chemistry research group, has acquired Synprosis, a France-based company specializing in the chemical synthesis of peptides and proteins for therapeutic use. The financial terms of the agreement have not been disclosed.

More... »


Adaptimmune, GlaxoSmithKline collaborate on cancer therapies

Tuesday, June 3, 2014 08:05 AM

Adaptimmune, a biotechnology company developing TCR engineered T-cells to treat cancer, has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of its lead clinical cancer program.

More... »

Roche acquires Genia Technologies to strengthen next generation sequencing pipeline

Monday, June 2, 2014 01:09 PM

Roche has acquired Genia Technologies, a privately held, California-based company. Genia is developing a single-molecule, semiconductor-based, DNA sequencing platform using nanopore technology.

More... »

Valeant, Pershing Square make revised offer for Allergan

Monday, June 2, 2014 01:07 PM

Valeant Pharmaceuticals International, a multinational specialty pharmaceutical company, has revised its offer for Allergan. Each Allergan share would be exchanged for $72 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of Allergan shares outstanding. This offer is subject to prompt good faith negotiation of a merger agreement between Valeant and Allergan. 

More... »

Agena Bioscience acquires Sequenom's Bioscience business

Monday, June 2, 2014 01:01 PM

Agena Bioscience, a portfolio company of Telegraph Hill Partners (THP), has acquired the Bioscience business of Sequenom, which sells the MassARRAY System for mass spectrometry-based detection of nucleic acids in research and clinical laboratories.

More... »

Senesco completes acquisition of Fabrus

Friday, May 23, 2014 02:34 PM

Senesco Technologies, a clinical stage biotech company specializing in cancer therapeutics, has completed its acquisition of Fabrus, a biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.

More... »

Abbott acquires CFR Pharmaceuticals, expanding Latin American presence

Monday, May 19, 2014 01:24 PM

Abbott will acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence.

More... »

AstraZeneca rejects Pfizer’s “final” acquisition offer

Monday, May 19, 2014 12:02 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Barely nine hours after Pfizer made its fourth and “final” takeover offer, raising it to $118 billion, AstraZeneca rejected it today, ending the U.S. pharma giant’s plan to create the world’s largest biopharmaceutical company.

More... »

Bayer to divest interventional device business to Boston Scientific

Friday, May 16, 2014 12:50 PM

Bayer HealthCare will sell its interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is $415 million.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs